Abstracts of the 2022 Annual Meeting of the ALEH
More infoViral hepatitis is a public health problem worldwide. In Paraguay, there is little information regarding which are the most frequently used treatments and the response obtained from them. This study aimed to report the results of hepatitis B treatment in two reference centers in Paraguay.
Materials and MethodsObservational, descriptive, retrospective. Excel for data collection. Variables are expressed in frequency, mean and percentages.
Results12,972 medical records were evaluated in the period 2000 - 2019, of which 171 (1.3%) had a diagnosis of Chronic Hepatitis B. Forty-four (26%) of the stories did not have sufficient information for the present analysis. Finally, 127 patients were studied. We had 30 patients in the cirrhotic stage, of which 20 patients (77%) had activity: Hepatitis B antigen e positive (Hepatitis HBeAg +), 11 patients (42%) and Hepatitis B antigen e negative (Hepatitis HBeAg -): 9 patients (35%). Considering all study participants, 47 (37%) were treated: 29 (62%) with Tenofovir disoproxil fumarate (TDF), 9 (19%) with lamivudine; 4 (9%) with entecavir, the rest, combinations of these and other drugs. Forty-two of those treated (89%) were Hepatitis HBeAg +. Of these, eight (19%) presented e-antigen seroconversion, in a mean time of 18.6 months (range 3 to 38 months). HBsAg seroclearance occurred in 3 (6.4% of the 47 treated); one of them was cirrhotic, all of them Westerners. The average time in which HBsAg seroclearance occurred was 12 months.
ConclusionsThe cases of hepatitis B treated in the Paraguayan centers studied, in the different phases of the disease, had a response (seroconversion of HBeAg and HBsAg seroclearance) similar to that reported in the literature.
